ArticleAmerican journal of translational research2025
Diagnostic superiority of contrast-enhanced ultrasound combined with elastography for early hepatocellular carcinoma in cirrhotic patients.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and combined application value of contrast-enhanced ultrasound (CEUS) and ultrasound elastography (USE) in diagnosing early hepatocellular carcinoma (HCC) in patients with liver cirrhosis.
methodsA total of 250 patients with cirrhosis, who were retrospectively analyzed between March 2021 and June 2024, were divided into an HCC group (n = 108) and a non-HCC group (n = 142). All patients underwent CEUS and USE examinations. Quantitative parameters such as peak intensity (PI), arrival time (AT), liver stiffness, and shear wave velocity (SWV) were analyzed. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curves.
resultsThe diagnostic accuracy of CEUS and USE alone was 84.0% and 84.8%, respectively, while their combined use increased the accuracy to 92.4% (P<0.05). CEUS demonstrated a higher sensitivity (87.0% vs. 78.7%), while USE had better specificity (89.4% vs. 81.7%). Among the quantitative parameters, the area under the curve for PI was 0.955, and for SWV, it was 0.988. The combined detection rate for small HCC (≤1 cm) increased from 66.7-72.2% with either method to 83.8%, and diagnostic accuracy for patients with Child-Pugh class A reached 94.1%.
conclusionThe combination of CEUS and USE significantly enhances the diagnostic accuracy for early-stage HCC in cirrhotic patients, particularly for those with small HCC and early cirrhosis. Quantitative parameter analysis offers an objective basis for optimizing screening strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.